Role of the Cytokine Profiles Produced by iNKT Cells in the Initial Phase of Cyclophosphamide-Induced Tolerance^1

iNKT 细胞产生的细胞因子谱在环磷酰胺诱导的耐受性初始阶段的作用^1

基本信息

  • 批准号:
    18390380
  • 负责人:
  • 金额:
    $ 11.21万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

Cyclophosphamide (CP) -induced tolerance is a mixed chimerism-based tolerance induction protocol. Recently, we reported that invariant natural killer T (iNKT) cells were essential for the tolerance induction in this system. In this study we evaluated the roles of the cytokines produced by iNKT cells. DBA/2 (H-2^d) mice and BALB/c(H-2^d)wild-type (WT) or iNKT knockout (KO) mice were used as donors and recipients. WT recipients received three doses(days -7. -4, -1 or 35, 38, 41)or a single dose (day -1 or 0) of a-galactosylceramide (GC) in conjunction with our conditioning regimen, which consisted of 10^8 donor spleen cells (SC) on day 0 and 200 mg/kg CP on day 2. To investigate the iNKT cell function, iNKT KO recipients were reconstituted with cytokine(IFN-y. IL-4,or IL-10)KO iNKT cells and received donor SC and CP.Mixed chimerism was observed in WT recipients, but was reduced in iNKT KO recipients. However, mixed chimerism was absent in WT recipients given GC on days -7, -4, -1, but not in WT recipients given GC on day 35, 38, 41. Donor skin grafts were chronically rejected when mixed chimerism was diminished. Skin grafts were accepted in iNKT KO recipients reconstituted with iNKT cells from IFN-y, IL-4, or IL-10 KO mice and receiving our conditioning regimen. iNKT cells were required in the initial phase of the induction of chimerism. Our results indicated that known major cytokines produced by iNKT cells were dispensable for the regulatory function of iNKT cells.
环磷酰胺(CP)诱导的耐受是一种基于混合嵌合体的耐受诱导方案。最近,我们报道了恒定的自然杀伤T(iNKT)细胞在该系统中的耐受诱导是必不可少的。在这项研究中,我们评估了iNKT细胞产生的细胞因子的作用。DBA/2(H-2_d)小鼠和BALB/c(H-2_d)野生型(WT)或iNKT敲除(KO)小鼠用作供体和受体。WT接受者接受三次剂量(第-7天)。-4、-1或35、38、41)或单剂量(第-1或0天)的α-半乳糖神经酰胺(GC)与我们的预处理方案联合,预处理方案由第0天10^8个供体脾细胞(SC)和第2天200 mg/kg CP组成。为了研究iNKT细胞功能,将iNKT KO受体用细胞因子(IFN-γ)重建。IL-4或IL-10)KO iNKT细胞并接受供体SC和CP。在WT受体中观察到混合嵌合体,但在iNKT KO受体中减少。然而,在第-7、-4、-1天给予GC的WT受体中不存在混合嵌合体,但在第35、38、41天给予GC的WT受体中不存在。当混合嵌合体减少时,供体皮肤移植物被慢性排斥。在用来自IFN-γ、IL-4或IL-10 KO小鼠的iNKT细胞重建并接受我们的预处理方案的iNKT KO受体中接受皮肤移植物。在嵌合体诱导的初始阶段需要iNKT细胞。我们的研究结果表明,已知的主要细胞因子产生的iNKT细胞的调节功能的iNKT细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance
NKT 细胞在诱导和维持环磷酰胺诱导耐受中的调节作用
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Iwai;T et al.
  • 通讯作者:
    T et al.
The Immunoregulatory role of Natural Killer T Cells in Cyclophosphamide-Induced Tolerance
自然杀伤 T 细胞在环磷酰胺诱导的耐受中的免疫调节作用
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tatsushi;Onzuka;Ichiro;Shimizu;Yukihiro;Tomita;Toshiro;Iwai;Shinji;Okano;Ryuji;Tominaga;Toshiro lwai
  • 通讯作者:
    Toshiro lwai
Influence of the Th1/Th2 paradigm for the regulatory function of the natural killer T (NKT) cells in cyclophosphamide (CP)-induced tolerance
Th1/Th2范式对环磷酰胺(CP)诱导的耐受中自然杀伤T(NKT)细胞调节功能的影响
Influence of the Th1/Th2 paradigm for the regulatory function of the natural killer T(NKT) cells in cyclophosphamide(CP) -induced tolerance.
Th1/Th2 范式对环磷酰胺 (CP) 诱导耐受中自然杀伤 T (NKT) 细胞调节功能的影响。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tatsushi;Onzuka;Ichiro;Shimizu;Yukihiro;Tomita;Toshiro;Iwai;Shinji;Okano;Ryuji;Tominaga
  • 通讯作者:
    Tominaga
Effects of Cyclosporirn A in the Activation of Natural Killer T Cells Induced by a-Galactosylceramide
环孢菌素 A 对α-半乳糖神经酰胺诱导的自然杀伤 T 细胞激活的影响
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    中川敦寛;隈部俊宏;小川欣一;平野孝幸;橋本時忠;中野徹;亀井尚;上之原広司;高山和喜;冨永悌二;Takashi kajiwara
  • 通讯作者:
    Takashi kajiwara
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TOMITA Yukihiro其他文献

TOMITA Yukihiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TOMITA Yukihiro', 18)}}的其他基金

Experimental organ transplantation: Application of the drug-induced immune tolerance-
实验性器官移植:药物诱导免疫耐受的应用-
  • 批准号:
    20390371
  • 财政年份:
    2008
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Induction of B cell tolerance against Gal-alpha(1-3)Gal Ag in Cyclophosphamide (CP)-induced tolerance
在环磷酰胺 (CP) 诱导的耐受中诱导 B 细胞对 Gal-alpha(1-3)Gal Ag 的耐受
  • 批准号:
    15390419
  • 财政年份:
    2003
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
cyclophosphamide plus Busulfan-induced tolerance in rat into mouse xenotransplantation
环磷酰胺加白消安诱导大鼠对小鼠异种移植的耐受性
  • 批准号:
    13671242
  • 财政年份:
    2001
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research on modeling of peripheral plasma in a field-reversed configuration
场反转配置中的外围等离子体建模研究
  • 批准号:
    11680492
  • 财政年份:
    1999
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
THE ANALYSIS OF THE MECHANISM OF ALLOGRAFT REJECTION USING KNOCK OUT MICES
基因敲除小鼠同种异体移植排斥机制分析
  • 批准号:
    09671384
  • 财政年份:
    1997
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Induction of drug induced tolerance in mice and application for large animals
小鼠药物耐受的诱导及其在大型动物中的应用
  • 批准号:
    07671312
  • 财政年份:
    1995
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research for rotational equilibrium and transport model of steady burning D-^3He plasma in the field-reversed configuration
场反转构型稳态燃烧D-^3He等离子体旋转平衡与输运模型研究
  • 批准号:
    05808041
  • 财政年份:
    1993
  • 资助金额:
    $ 11.21万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 11.21万
  • 项目类别:
Early life bladder inflammatory events in female mice lead to subsequent LUTS in adulthood
雌性小鼠生命早期的膀胱炎症事件导致成年后的 LUTS
  • 批准号:
    10638866
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Ex vivo whole ovary culture system for screening gonadotoxicity during drug development
用于在药物开发过程中筛选性腺毒性的离体全卵巢培养系统
  • 批准号:
    10823136
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
  • 批准号:
    10713034
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
调节PD-1/PD-L1检查点促进肉瘤患者HER2 CAR T细胞的抗肿瘤活性
  • 批准号:
    10562836
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Chromatin regulators of stemness and therapy resistance in rhabdomyosarcoma
横纹肌肉瘤干性和治疗耐药性的染色质调节因子
  • 批准号:
    10622041
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Circadian Rhythms in Blood Brain Barrier Permeability and Increased Efficacy of Chemotherapy for Brain Metastases
血脑屏障通透性的昼夜节律和脑转移化疗疗效的提高
  • 批准号:
    10663717
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation
将来自免疫活性干细胞供体的疫苗诱导的免疫力转移作为抗病毒免疫疗法,以保护高危移植受者免受巨细胞病毒再激活
  • 批准号:
    10659635
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Bispecific Antibody Maintenance Therapy after Allogeneic Bone Marrow Transplant
同种异体骨髓移植后的双特异性抗体维持治疗
  • 批准号:
    10572777
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
Applications of the long-term culture human primordial germ cell-like cells to toxicological assessments and mechanistic studies on chemically caused heritable human health threats
长期培养人类原始生殖细胞样细胞在化学引起的遗传性人类健康威胁的毒理学评估和机制研究中的应用
  • 批准号:
    10666200
  • 财政年份:
    2023
  • 资助金额:
    $ 11.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了